TargetBeta
CNR1
cannabinoid receptor 1 · also CB1K5, CB-R, CB1, CANN6 · Cannabinoid receptors
4 programs in company-led studies act on CNR1, from 3 companies: 2 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Cannabidiolrule | Jazz Pharmaceuticals | phase 4 | 688 running | – | ChEMBL |
| Rimonabantrule | Sanofi | phase 3 | 383 running | – | ChEMBL |
| Dronabinolrule | Jazz Pharmaceuticals | phase 3 | 202 running | – | ChEMBL |
| CRB-913rule | Corbus Pharmaceuticals | phase 1 | 10 running | – | the studies' text |
Conditions their studies are in
- Obesity, 2 programs
- Cancer Pain, 1 program
- Diabetes Mellitus, Type 2, 1 program
- Epilepsies, Myoclonic, 1 program
- Epilepsy, 1 program
- Fasting, 1 program
- Fatty Liver, 1 program
- Lennox Gastaut Syndrome, 1 program
- Pain, 1 program
- Post-Acute COVID-19 Syndrome, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 2027Dronabinol · Jazz Pharmaceuticals · phase 3 · NCT07635563
- Aug 2027Rimonabant · Sanofi · phase 3 · NCT07843108
- Aug 1, 2027Cannabidiol · Jazz Pharmaceuticals · phase 4 · NCT05044819
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.